Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable pharmaceutical manufacturing, announced that its team plans to attend the second annual BioLogic Summit, taking place January 19-22, 2026, in San Diego. The summit is a premier event centered on the application of machine learning and artificial intelligence for the design and optimization of biotherapeutics.
Quantumzyme’s participation underscores its strategic commitment to remaining engaged in the rapidly evolving fields of AI-enabled enzyme engineering and protein design. The conference offers an opportunity for the company’s scientific leadership to participate in technical discussions, share insights with peers, and explore emerging advancements in disciplines that align with its internal development efforts and its proposed strategic evolution to Quantum Genesis AI Corp., pending FINRA approval.
The BioLogic Summit is specifically designed for the growing community of hybrid scientists who integrate experimental and computational methods—a profile that reflects the expertise of the Quantumzyme team. By attending, the company aims to stay informed on the latest developments in generative AI, lab-in-the-loop optimization, and structure-based design approaches. These insights are intended to support the continued advancement of the company’s platform and help ensure it remains aligned with the most relevant methodologies in the field.
“Innovation doesn’t happen in isolation. Being present and actively engaging with the brightest minds in our field is essential to driving our mission forward,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “The BioLogic Summit provides a valuable venue for our team to connect with individuals and organizations who are contributing to the future of AI in biologics. Our goal is to learn from the latest research, better understand emerging challenges, and explore potential collaborations that may support the adoption of greener and more efficient manufacturing approaches across the pharmaceutical industry.”
For more information and updates, please visit www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
